STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
Navin Pinto(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Sowmya Pattabhi, Rimas J. Orentas(Capital Caring), Joshua A. Gustafson(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Heather H. Gustafson(Seattle Children's Hospital), Katelyn Burleigh(Seattle Children's Hospital), Nicholas A. Vitanza(Seattle Children's Hospital), Catherine M. Albert(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Christopher Brown, Wenjun Huang(Lishui Central Hospital), Jason Wendler(Pacific Northwest National Laboratory), Rebecca Gardner(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Safia Cheeney(Seattle Children's Hospital), Heidi B. Ullom(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital)
Cited by 46
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754